The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.
Napa Parinyanitikul
No relevant relationships to disclose
Xiudong Lei
No relevant relationships to disclose
Mariana Chavez-Mac Gregor
No relevant relationships to disclose
Elizabeth Ann Mittendorf
No relevant relationships to disclose
Jennifer Keating Litton
No relevant relationships to disclose
Wendy A. Woodward
No relevant relationships to disclose
Hong Zhang
No relevant relationships to disclose
Gabriel N. Hortobagyi
No relevant relationships to disclose
Ana M. Gonzalez-Angulo
No relevant relationships to disclose